Why Immix Biopharma, Inc.’s (IMMX) Stock Is Up 7.54%
As of Wednesday, August 19, Immix Biopharma, Inc.’s IMMX share price has surged by 7.54%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Commentary & Analysis
Why Immix Biopharma, Inc.’s (IMMX) Stock Is Up 5.25%
As of Monday, August 10, Immix Biopharma, Inc.’s IMMX share price has surged by 5.25%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Immix Biopharma, Inc.’s (IMMX) Stock Is Down 5.86%
As of Friday, August 07, Immix Biopharma, Inc.’s IMMX share price has dipped by 5.86%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Immix Biopharma, Inc.’s (IMMX) Stock Is Up 6.18%
As of Tuesday, August 04, Immix Biopharma, Inc.’s IMMX share price has surged by 6.18%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Immix Biopharma, Inc.’s (IMMX) Stock Is Up 7.39%
As of Monday, July 27, Immix Biopharma, Inc.’s IMMX share price has surged by 7.39%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | IMMX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $941.5 | $286.3 | 44% |
|
| Shares Out (Mil) | 63.8 | 54.2 | 53% |
|
| Institutional Ownership | 85.6% | 92.8% | 53% |
|
| Float (Mil) | 56.2 | 39.7 | 50% |
|
| Beta | 0.11 | 0.94 | 9% |
|
| Avg Daily Volume (000s) | 1,525 | 534 | 77% |
|
| Price Change (52-week) |
500.9% | 58.7% | 99% |
|
| Growth | IMMX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (92.9%) | (10.1%) | 2% |
|
| EPS (5yr) | (21.3%) | 16.0% | 12 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 90.5% | (15.6%) | 98% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 8 | 8 | |
| Current EPS | ($0.192) | ($0.744) | ($0.904) | |
| Month Ago EPS | ($0.172) | ($0.691) | ($0.742) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.203) | ($0.746) | ($0.713) | |
| Year/Year Chg | 6.1% | (16.7%) | (25.5%) | |
| Financials | IMMX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($40) | ($43) | 18% |
|
| EPS (TTM) | ($0.834) | ($1.400) | 23% |
|
| Operating Cash Flow (TTM) (Mil) | ($39) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $214 | $2 | 85% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 16% |
|
| Enterprise Value (Q1) (Mil) | $464 | $160 | 33% |
|
| Valuation | IMMX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.11 | 2.77 | 73% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | IMMX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (31.3%) | (47.3%) | 16% |
|
| ROE | (34.2%) | (55.0%) | 19% |
|
| Liabilities to Assets | 4.3% | 29.6% | 2% |
|
| F-Score | 3 | 2 | 18% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.4% |
| +/- S&P 500: | -5.1 |
